- Joined
- 1 January 2007
- Posts
- 317
- Reactions
- 1
Thanks Homer J - Well I'm sure this has already been taken into account with todays price if it's 99% done... But you never know..
Thanks
SLA - Solagran Limited
- Thread starter yogi-in-oz
- Start date
-
- Tags
- sla solagran limited
Thanks Homer J - Well I'm sure this has already been taken into account with todays price if it's 99% done... But you never know..
Thanks
- Joined
- 1 January 2007
- Posts
- 317
- Reactions
- 1
An interesting close... a couple of big orders going through towards the end100k and some smaller ones.. I think SLA is a good long term hold.... but I had taken some interest as I was going to sell this to make an offset... but after seeing it today I have held on for a while.... Luck I was going to dust off the cobwebs and sell...
- Joined
- 23 February 2007
- Posts
- 165
- Reactions
- 0
- Joined
- 23 February 2007
- Posts
- 165
- Reactions
- 0
to all the holders I think this is it
TRADING HALT
ropren approved .???..
anybody other thoughts??
looks like we will know on wednesday
TRADING HALT
ropren approved .???..
anybody other thoughts??
looks like we will know on wednesday
- Joined
- 11 March 2007
- Posts
- 4
- Reactions
- 0
Hey all,
yeah, for mine Trading Halt is for Approval and EGM notification. Hopefully hear tomorrow! Another day of suspense i dont think i could deal with!! hehe
Id also say that it could be Alcoholic and Drug Trial results, but everything seems held back till approval.
Once Approval is announced we'll have trial results released, very interesting EGM notification(including intrinsic valuation report), a future deal with Big Pharma for Ropren worldwide(huge!), alot more publicity etc etc
Also waiting on Bio A partner, and sales update for A+B.
Lots of positives in the wings-would say i cant wait, but i guess im going to have to!!
BB
yeah, for mine Trading Halt is for Approval and EGM notification. Hopefully hear tomorrow! Another day of suspense i dont think i could deal with!! hehe
Id also say that it could be Alcoholic and Drug Trial results, but everything seems held back till approval.
Once Approval is announced we'll have trial results released, very interesting EGM notification(including intrinsic valuation report), a future deal with Big Pharma for Ropren worldwide(huge!), alot more publicity etc etc
Also waiting on Bio A partner, and sales update for A+B.
Lots of positives in the wings-would say i cant wait, but i guess im going to have to!!
BB
- Joined
- 1 January 2007
- Posts
- 317
- Reactions
- 1
Hey smoothred, Where did you heard that the ann is coming out on Wed? Just interested as I would have thought it was tomorrow.. Thanks
- Joined
- 1 January 2007
- Posts
- 317
- Reactions
- 1
Hey smoothred, ops sorry found it in the ann.. Thanks for highlighting this to me... pro trader had not had it flagged.... cheers..
- Joined
- 1 January 2007
- Posts
- 317
- Reactions
- 1
Hey Guys,
It seems the press have already published the ann in the paper.. Today will be a great day for SLA holders
http://www.news.com.au/heraldsun/story/0,21985,22092194-664,00.html
John Beveridge
July 18, 2007 12:00am
A SMALL Melbourne biotechnology company has achieved a major breakthrough after getting pharmaceutical registration in Russia.
Solagran will today announce that its drug Ropren can be prescribed for liver disease in Russia.
That means the drug should start to sell in Russia this year, with the next development steps being to seek approval in the rest of Europe and the United States.
Trials have shown Ropren and its active ingredient Bioeffective R is highly effective in treating chronic liver diseases including various forms of hepatitis and cirrhosis.
Further trials both in Russia and Melbourne have also shown Ropren could also be effective in normalising blood lipids such as cholesterol and in treating and preventing neurodegenerative conditions such as Alzheimers and Parkinson's disease.
Solagran shares have been in a trading halt since Monday pending today's announcement.
They have traded from a low of 17 in September last year to a high of $1.55 in May this year.
Solagran has already announced that it is dramatically ramping up European production of Ropren to cater for the estimated 10 million people with liver disease in Russia.
Unlike most drugs, the active ingredient in Ropren is a natural compound known as a polyprenol that is isolated from green conifer needles.
It was first developed in Russia by Professor Victor Roschinback in 1986.
Since Solagran listed in 2003, executive chairman Dr Vagif Soultanov and a Russian project team have successfully pushed to have the drug registered in Russia.
That registration process was shortened significantly because clinical trials showed Ropren to be effective without any of the usual side effects of liver disease drugs.
The Russian Ministry of Health was also keen to introduce a locally discovered drug to combat the high number of liver disease sufferers in the country.
Initially supply of Solagran will be restricted by production, so most treatment courses will be prescribed in Moscow and St Petersburg.
Capacity expansion should see supply grow to the rest of Russia over the next few years.
Given Ropren has pharmaceutical approval in Russia, it may also be used when indicated to treat situations other than its primary role in restoring liver function.
That could include novel applications such as helping to prevent neuronal cell death in the brain following heart attack or stroke and conditions associated with drug and alcohol addiction.
It seems the press have already published the ann in the paper.. Today will be a great day for SLA holders
http://www.news.com.au/heraldsun/story/0,21985,22092194-664,00.html
John Beveridge
July 18, 2007 12:00am
A SMALL Melbourne biotechnology company has achieved a major breakthrough after getting pharmaceutical registration in Russia.
Solagran will today announce that its drug Ropren can be prescribed for liver disease in Russia.
That means the drug should start to sell in Russia this year, with the next development steps being to seek approval in the rest of Europe and the United States.
Trials have shown Ropren and its active ingredient Bioeffective R is highly effective in treating chronic liver diseases including various forms of hepatitis and cirrhosis.
Further trials both in Russia and Melbourne have also shown Ropren could also be effective in normalising blood lipids such as cholesterol and in treating and preventing neurodegenerative conditions such as Alzheimers and Parkinson's disease.
Solagran shares have been in a trading halt since Monday pending today's announcement.
They have traded from a low of 17 in September last year to a high of $1.55 in May this year.
Solagran has already announced that it is dramatically ramping up European production of Ropren to cater for the estimated 10 million people with liver disease in Russia.
Unlike most drugs, the active ingredient in Ropren is a natural compound known as a polyprenol that is isolated from green conifer needles.
It was first developed in Russia by Professor Victor Roschinback in 1986.
Since Solagran listed in 2003, executive chairman Dr Vagif Soultanov and a Russian project team have successfully pushed to have the drug registered in Russia.
That registration process was shortened significantly because clinical trials showed Ropren to be effective without any of the usual side effects of liver disease drugs.
The Russian Ministry of Health was also keen to introduce a locally discovered drug to combat the high number of liver disease sufferers in the country.
Initially supply of Solagran will be restricted by production, so most treatment courses will be prescribed in Moscow and St Petersburg.
Capacity expansion should see supply grow to the rest of Russia over the next few years.
Given Ropren has pharmaceutical approval in Russia, it may also be used when indicated to treat situations other than its primary role in restoring liver function.
That could include novel applications such as helping to prevent neuronal cell death in the brain following heart attack or stroke and conditions associated with drug and alcohol addiction.
Caliente
Black Gold!
- Joined
- 30 May 2005
- Posts
- 492
- Reactions
- 0
just a cut and paste from my last post at hotcopper///.
I've been a longtime critic of SLA, just ask pacer at ASF but todays announcement has convinced me that at LEAST the Russian Medical Board are convinced about the efficacy of Ropren as a hepatoprotector.
I myself am not and wont be until we get TGA (aus) or FDA (US) approval for Ropren... but I'm not going to hang around any longer and watch the SP get away! (my first bagging of SLA was back in the 20 cent region!).
So lock me in for the ride to 2012 =)
I'm sure you all agree once Ropren expands SibEX and goes global its a veritable gravy train.
[I would advise you all bail if Ropren fails TGA approval here - although given Bio A's approval here that seems to be an increasingly unlikely scenario.]
Cheers
-Cali
I've been a longtime critic of SLA, just ask pacer at ASF but todays announcement has convinced me that at LEAST the Russian Medical Board are convinced about the efficacy of Ropren as a hepatoprotector.
I myself am not and wont be until we get TGA (aus) or FDA (US) approval for Ropren... but I'm not going to hang around any longer and watch the SP get away! (my first bagging of SLA was back in the 20 cent region!).
So lock me in for the ride to 2012 =)
I'm sure you all agree once Ropren expands SibEX and goes global its a veritable gravy train.
[I would advise you all bail if Ropren fails TGA approval here - although given Bio A's approval here that seems to be an increasingly unlikely scenario.]
Cheers
-Cali
15 August, 2007
Company Announcement
Supply and Pricing of Ropren outside Russia
The Directors of Solagran Limited are pleased to provide an update regarding the supply and
pricing of Ropren outside Russia.
Since the full results of the Ropren liver disease clinical trials were presented to 2,500
clinicians and researchers at an international gastroenterology conference in St Petersburg
in May, and particularly since Ropren received final regulatory approval from the Russian
Ministry of Health in July, Solagran and its manufacturing partner in St Petersburg have
received a steady stream of enquiries regarding the availability of Ropren for patients with
cirrhosis and other serious liver diseases living in the UK, Western Europe, Scandinavia,
North America and Asia. There have also been many enquiries from doctors in the former
Soviet Republics (CIS countries).
In response to these requests, our manufacturing partner has decided to put in place the
necessary administrative procedures to enable them to provide Ropren to patients outside
Russia consistent with the specific “compassionate use” and “personal supply” provisions
that exist within the regulatory frameworks of each country.
As part of that decision making process, it was necessary for them to consult with Solagran
to set a price for the supply of Ropren to patients outside Russia who requested supply
under the appropriate regulatory provisions. Solagran has agreed to a price in the range
3,500 to 6,000 US Dollars per three month course.
Solagran has independently confirmed that this price compares very favourably with other
therapies currently used to treat serious liver diseases.
The pricing of Ropren in Russia will be resolved with the Russian Ministry of Health in
conjunction with the granting of a manufacturing licence. This is expected to occur at the
latest in November.
Peter Stedwell
Company Secretary
On behalf of the Board of Directors
Solagran Limited
- Joined
- 29 May 2007
- Posts
- 6
- Reactions
- 0
The recent EGM revealed some useful information in relation to directors interest notices and announcements.
The directors have openly stated that they have a deliberate policy of only purchasing on market after announcments are made to the market to ensure their actions are always considered to have integrity. They have also stated that they will buy to support share price at certain levels
I would take this as recent change of directors notices means there is no price sensitive announcements imminent.
I hold SLA
The directors have openly stated that they have a deliberate policy of only purchasing on market after announcments are made to the market to ensure their actions are always considered to have integrity. They have also stated that they will buy to support share price at certain levels
I would take this as recent change of directors notices means there is no price sensitive announcements imminent.
I hold SLA
